The absolute best we can hope for:
1. NNVC does in fact select a candidate for ocular Herpescide by the end of this year. That is all they expect to accomplish according to their SEC filings. And of course NNVC has never yet met any of their own time tables. So far we have no indication that any samples have even gone out to any of the universities doing the testing, so this optimistic time table requires that an awful lot be done in the next four months after 8 months of no discernable progress.
2. Then the best we can hope for is that NNVC somehow gets tox done before 2017 is over. Remember that in 2014 it took a full year to make 200g of Flucide (nowhere near enough to complete tox) and then do the little bit of tox testing that could be done with that 200g. So I say one full year to get Herpescide tox done. Minimum.
3. So, we will be at the end of 2017 with no clinical trials in sight. But wait -- NNVC can't do clinical trials until it gets IND approval from the FDA. Figure at least 6 months for this -- it involves the federal government.
So, like I said, no clinical trials for Herpescide in 2016 or 2017. Bank on it. There's a very good chance that there will be no clinical trials in 2018, either, as NNVC typically misses its time tables by factors of 2 or more.
Market Data 
Markets 
AI
